Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” first quarter 2025 ...

With a market cap of around $136 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company. The Foster City, ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Shares of Gilead Sciences Inc. GILD slid 1.06% to $108.91 Monday, on what proved to be an all-around favorable trading ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...